Program
TR115
A development code.
Its studies are mostly in Endometrial Neoplasms · Lymphoma, Extranodal NK-T-Cell · Lymphoma, Non-Hodgkin, led by Tarapeutics Science.
Furthest: phase 3, since May 26, 20263 company-led studies, 3 open or runningNext primary completion: May 1, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tarapeutics Science | 33 open or running | phase 3since May 26, 2026 | Dec 6, 2022 | May 1, 2028phase 2 · NCT07793318 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 6, 2022First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05650580 · 26 planned · China
- May 26, 2026Phase 3 study in Lymphoma, Extranodal NK-T-CellPhase 3 reachedNCT07639879 · 180 planned · China
- Aug 25, 2026Phase 2 study in Endometrial NeoplasmsNCT07793318 · 50 planned · China
Ahead
- May 1, 2028Primary completion: phase 2 study in Endometrial NeoplasmsNCT07793318
- Jul 30, 2029Primary completion: phase 3 study in Lymphoma, Extranodal NK-T-CellNCT07639879
TargetBeta
EZH2 →read by rule
“This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.”study text, by rule · the study
Other programs on EZH2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zeprumetostatrule | Jiangsu HengRui Medicine | phase 3 | 17 |
| mevrometostat | Pfizer | phase 3 | 7 |
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07793318Endometrial Neoplasms · China | 2 | Not yet recruiting | May 1, 2028 | 50 |
| NCT07639879Lymphoma, Extranodal NK-T-Cell · China | 3 | Not yet recruiting | Jul 30, 2029 | 180 |
| NCT05650580Lymphoma, Non-Hodgkin · China | 1 | Recruiting | Jul 30, 2025 | 26 |
How it is read
Names in the registry
- “TR115”, 3 entries
Codes read as this program: TR115.
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 1 study
- Lymphoma, Extranodal NK-T-Cell, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.